Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.49 |
| ▸ | HTR2C | P28335 | 5/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18911621 | 0.74 | HTR2A (0.73) | HTR2AHTR2CNOTUMSIGMAR1HTR1A | |
| SCHEMBL29851785 | 0.71 | HTR2A (0.40) | HTR2AHTR2CNOTUMSIGMAR1 | |
| SCHEMBL1873666 | 0.71 | NOTUM (0.42) | HTR2AHTR2CNOTUMSIGMAR1 | |
| SCHEMBL1864062 | 0.71 | HTR2A (0.40) | HTR2AHTR2CNOTUMSIGMAR1 | |
| SCHEMBL13403405 | 0.68 | NOTUM (0.47) | HTR2AHTR2CNOTUMSIGMAR1HTR1A | |
| Hydroxyamine SCHEMBL9656520 | 0.67 | HTR2A (0.37) | HTR2AHTR2CNOTUMSIGMAR1 | |
| Hydroxyamine SCHEMBL9656514 | 0.67 | NOTUM (0.39) | HTR2AHTR2CNOTUMSIGMAR1 | |
| SCHEMBL3211491 | 0.67 | HTR2A (0.37) | HTR2AHTR2CNOTUM | |
| SCHEMBL761931 | 0.67 | HTR2A (0.64) | HTR2AHTR2CNOTUMSIGMAR1HTR1A | |
| SCHEMBL30703022 | 0.67 | HTR2A (0.64) | HTR2AHTR2CNOTUMSIGMAR1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3294712-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD Pharmaceuticals, Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| WO-2016183278-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016183278-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | HTR2A 1012/4885HTR2C 642/4885NOTUM 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.